Table 22. Survival of Patients with CRC PC Treated by CRS and HIPEC and/or EPIC and/or SC: Summary of 76 Researches.
| Author/ Years/ Country | 1-yr SR (%) | 2-yr SR (%) | 3-yr SR (%) | 4-yr SR (%) | 5-yr SR (%) | Mortality Rate (%) |
Morbidity Rate (%) |
Median OS (mo) |
OS 95% CI (mo) |
PFS(95% CI) (mo) | DFS/RFS (95% CI) (mo) |
Follow-up times (range) (mo) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HIPEC single arm studies | ||||||||||||
| Desantis/ 2014/ France [48] | ≈88 | ≈72 | 60.3 | ≈47 | 37 | 1 (all) | 12.5 (all) | 45.9 | NR | NR | 16.8 1-,3-,5-yr 61.3%, 30.4% and 22.8% |
NR |
| Elias/ 2004/ France [49] | 83 | 74 | 65 | NR | NR | 8.3 | 41.6 | NR | NR | NR | 18 1-,2-,3-yr 61%, 50% and 50% |
27.4 (18.3-49.6) |
| Elias/ 2014/ France [50] | 91.4 | ≈74 | 54 | ≈47 | 36.5 | 4.2 | 17 | ≈41 | NR | NR | NR | 62.4 (55.6-77.6) |
| Evers/ 2011/ Netherlands [51] | NR | NR | NR | NR | 36 | NR | NR | 49.2 vs. 41.3 (Ovarian metastases vs. without ovarian metastases) |
NR | NR | 36.9 vs. 32.5 (Ovarian metastases vs. without ovarian metastases) |
22 (1 week – 97 mo) |
| Faron / 2016/ France [100] | NR | NR | NR | NR | 42 | 4.6 | 47 | 41 | 32-50 | NR | 17.7 (12-19) 5-yr: 14% |
48.5 (41.0-56.3) |
| Franko/ 2008/ America [52] | ≈79 (MVR) ≈12 (NVR) |
≈46 (MVR) ≈30 (NVR) |
≈31 (MVR) ≈30 (NVR) |
≈16 (MVR) ≈30 (NVR) |
0 (MVR) ≈15 (NVR) |
1.4 | 60 | 20.2 (MVR) 14.3 (NVR) |
NR | NR | NR | NR |
| Frøysnes/ 2016/ Norway [103] | ≈93 | ≈78 | 65 | ≈45 | 36 | 0 | 15.1 | 47 | 42-52 | NR | 10 (7-12) | 45 (35-55) |
| Glehen/ 2003/ France [53] | NR | NR | NR | NR | NR | 1.8 (all) | 28.6 (all) | 17.5 | 4.4-53.6 | NR | NR | 18.1 (4.4-56) (all) |
| Glehen/ 2004/ France [16] | 55 | 32 | NR | NR | 11 | 4 | 23 | 12.8 | NR | NR | NR | 59.5 (2-148) |
| Glehen/ 2010/ France [54] | ≈80 | ≈56 | 41 | ≈33 | 26 | 4.1 (all) | 33.6 (all) | 30 | NR | NR | 1-,3-,5-yr 77%, 49% and 37% | 45.3 (20.3-90.9) (all) |
| Gomes / 2005/ America [55] | ≈60 | ≈30 | ≈20 | ≈20 | 0 | NR | NR | 20 | NR | NR | NR | 15.7 (1-51) |
| Gusani/ 2008/ America [56] | ≈74 | ≈49 | ≈49 | ≈39 | NR | 0 | 29.8 (all) | ≈23.6 | NR | NR | NR | 35.9 (19.0-57.7) (all) |
| Hamilton/ 2011/ Canada [57] | ≈79 | ≈62 | 38 | ≈34 | 34 | NR | NR | 27 | 0-87 | NR | 9 (0-87) 3-,5-yr 34%,26% |
28 (0-119) (all) |
| Hompes/ 2012/ Belgium [58] | 97.9 | 88.7 | ≈84 | NA | NA | 0 | 52.1 | NA | NA | NR | 19.8 (12–upper limit not defined) (RFS) | 22.7 (3.2-55.7) |
Note: yr: year; SR: survival rate; mo: months; OS: overall survival; PFS: progression-free survival; RFS: recurrence-free survival; DFS: disease-free survival; NA: not achieved; NR: not reported; PMP: pseudomyxoma peritonei; L-OHP: oxaliplatin; MMC: mitomycin; all: all tumors in researches; MVR: multivisceral resection group; NVR: No visceral resection group; APP: appendix; NNT: non-neoadjuvant therapy; NCA: neoadjuvant chemotherapy alone; NCB: neoadjuvant chemotherapy + bevacizumab; AC: adjuvant chemotherapy; NAC: non- adjuvant chemotherapy